肺动脉高压靶向药物治疗的研究进展  

Research Progress of Targeted Drug Therapy for Pulmonary Arterial Hypertension

作　　者：王瑞[1] 武云[1] WANG Rui;WU Yun(Department of General Medicine,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学第一附属医院全科医学科,乌鲁木齐830000

出　　处：《医学综述》2022年第9期1776-1783,共8页Medical Recapitulate

基　　金：新疆维吾尔自治区研究生创新项目(XJ2021G229)。

摘　　要：肺动脉高压(PAH)是由多种原因导致的常见病症,被称为“心血管癌症”,具有病死率高、预后差的特点。以往的治疗方案主要包括一般措施治疗、基础治疗及特异性治疗,但治疗效果仍不理想。随着靶向药物的应用,PAH患者的预后明显改善。PAH是多种病理生理途径致病,使用单一靶向药物治疗的总体效果欠佳,故靶向药物联合治疗成为重要的治疗方案,可极大改善患者的临床症状,提高患者生活质量。但目前对于靶向药物联合治疗的药物选择仍存在困惑,需要深入研究。Pulmonary arterial hypertension(PAH),a common condition caused by multiple causes,is known as"cardiovascular cancer",and characterized by high mortality and poor prognosis.The previous treatment schemes mainly include general measures,basic treatment and specific treatment,but the therapeutic effect remains unsatisfactory.With the application of targeted drugs,the prognosis of PAH patients has improved significantly.However,PAH is caused by many pathophysiological ways,and the overall effect of treatment with single targeted drugs is not good.Therefore,the combination treatment of targeted drugs has become an more important treatment plan,which can greatly improve the clinical symptoms and improve their quality of life of the patients.However,there is still confusion about the choice of targeted drugs for the combination therapy,which needs further studies.

关 键 词：肺动脉高压 联合治疗 靶向药物 

分 类 号：R543[医药卫生—心血管疾病]